

Reference FOIAH2425/363 Number:

From: Private Individual

Date: 07 October 2024

Subject: Treatment of Cancer using a Specific Combination of Drugs

- Q1 In the past 6 months, at your trust how many patients were treated with a combination of Dabrafenib + Trametinib for the following conditions:
 - A) Metastatic Melanoma
 - B) Adjuvant Melanoma
 - C) C) BRAF mutated Lung Cancer
- A1 Information not held the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q2 In the past 6 months, at your trust how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following conditions:
 - A) Metastatic Melanoma
 - B) Colorectal Cancer
- A2 Information not held the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.